Artefenomel-Ferroquine — Competitive Intelligence Brief

Artefenomel-Ferroquine (Artefenomel-Ferroquine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial. Area: Infectious Diseases.

phase 2 Antimalarial Plasmodium falciparum Infectious Diseases Small molecule

Target snapshot

Artefenomel-Ferroquine (Artefenomel-Ferroquine) — Centre de Recherche Médicale de Lambaréné. Artefenomel-Ferroquine is a combination of artefenomel and ferroquine, which targets the Plasmodium falciparum parasite.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Artefenomel-Ferroquine TARGET	Artefenomel-Ferroquine	Centre de Recherche Médicale de Lambaréné	phase 2	Antimalarial	Plasmodium falciparum
Pyronaridine artesunate	Pyronaridine artesunate	Medicines for Malaria Venture	marketed	Antimalarial combination	Plasmodium falciparum DNA; heme detoxification pathway
Artemether + Lumefantrine	Artemether + Lumefantrine	GlaxoSmithKline	marketed	Antimalarial combination	Plasmodium falciparum hemoglobin metabolism and heme detoxification pathway
Artesunate + Amodiaquine	Artesunate + Amodiaquine	Professor Anders Björkman	marketed	Antimalarial combination	Plasmodium falciparum hemoglobin metabolism and DNA synthesis
SP-IPTp	SP-IPTp	London School of Hygiene and Tropical Medicine	marketed	Antimalarial combination therapy	Plasmodium falciparum dihydrofolate reductase (sulfadoxine-pyrimethamine); hemozoin formation (piperaquine)
artesunate-lapdap	artesunate-lapdap	London School of Hygiene and Tropical Medicine	marketed	Antimalarial combination	Plasmodium falciparum dihydrofolate reductase (lapdap component); artemisinin mechanism not fully elucidated but involves heme interaction
DHA/piperaquine and a SLD-PQ	DHA/piperaquine and a SLD-PQ	University of Oxford	marketed	Artemisinin-based combination therapy (ACT)	Plasmodium falciparum and other malaria parasites (multiple targets including heme detoxification pathway)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial class)

1. London School of Hygiene and Tropical Medicine · 6 drugs in this class
2. Sanofi · 3 drugs in this class
3. Epicentre · 2 drugs in this class
4. University of Oxford · 2 drugs in this class
5. · 2 drugs in this class
6. Frantz Viral Therapeutics, LLC · 1 drug in this class
7. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
8. Institut de Recherche pour le Developpement · 1 drug in this class
9. Centre de Recherche Médicale de Lambaréné · 1 drug in this class
10. GlaxoSmithKline · 1 drug in this class